Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Nvidia ...

Novo Nordisk, on the other hand, has taken a significant step by submitting a higher dose of its obesity treatment, Wegovy, to the European Medicines Agency. In the United States, the healthcare ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug ...

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo ...

Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Under the agreement, the two institutions will co-develop programmes across three key areas: health system capacity building, ...